We are international
Donate
• treatment options TEXT SIZE   
stem cell transplant    back

Myeloma Minute
December 17, 2008
12.17.08

Welcome to the IMF's Myeloma Minute
News about myeloma treatment, research, support and the myeloma community
from the International Myeloma Foundation.

SPECIAL EDITION

MOZOBIL™ APPROVAL COULD BENEFIT MYELOMA PATIENTS
UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTS

-The FDA Has Granted Marketing Authority for Mozobil with Granulocyte-Colony Stimulating Factor in Patients with Multiple Myeloma and Non-Hodgkin's Lymphoma-

Many patients scheduled for stem cell transplants could benefit from the FDA approval of Mozobil™ (plerixa for injection). Mozobil releases biological bonds that hold stem cells to the bone marrow so they travel into the blood stream where they are available for harvest. The regimen was approved for patients with multiple myeloma and non-Hodgkin's lymphoma (NHL) in preparation for autologous stem cell transplantation, a standard of care for patients meeting certain medical conditions.

"We believe Mozobil can help patients who are candidates for transplant by increasing the number of stem cells available to be harvested, and shortening the amount of time required for that harvest to take place, "said Susie Novis, President of the IMF. "We applaud new developments such as this with the potential to ease the burden on patients, and reduce the resources required for their care."

According to the Genzyme Corporation that makes Mozobil, studies have shown that the median time required to collect the target number of stem cells was just one day for patients given Mozobil, while patients on placebo required a median number of four days for the required number of cells to be collected.  The target number of stem cells required for harvest is at least 6 million cells per kg of body weight.

Stem cell transplantation is an option for many myeloma patients upon completion of frontline therapy. Eligibility for autologous stem cell transplantation is based on factors including patient age and general health, type of myeloma, stage of myeloma, disease aggressiveness and responsiveness to treatment.

Mozobil is now approved for use in the United States in combination with granulocyte-colony stimulating factor (G-CSF). Approval is pending in Europe, Australia, and Brazil with additional applications planned.




Many thanks to the supporters of The Myeloma Minute:
Celgene Corporation, Millennium Pharmaceuticals and The Binding Site.
Please call the hotline (800) 452-CURE (800-452-2873) or email TheIMF@myeloma.org if you have any questions.
Copyright 2008. International Myeloma Foundation. All Rights Reserved.

 related articles
Myeloma Minute
April 1, 2010
Myeloma Minute
April 14, 2010
Myeloma Minute
April 5, 2009
Myeloma Minute
April 6, 2009
Myeloma Minute
August 18, 2010
Myeloma Minute
August 4, 2010
Myeloma Minute
February 11, 2009
Myeloma Minute
February 25, 2009
Myeloma Minute
February 5, 2009
Myeloma Minute
January 26, 2009
Myeloma Minute
June 5, 2009
Myeloma Minute
March 1, 2009
Myeloma Minute
March 22, 2009
Myeloma Minute
November 22, 2009
Myeloma Minute
November 29, 2010
Myeloma Minute
October 26, 2010
Myeloma Minute
July 7, 2009
Myeloma Minute
September 2, 2010